

2021 2Q Fact Sheet

Jeisys

Disclaimer

► it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to uncertainties, changes in the organizational structure, redefinition of accounting policies, etc., and may cause the actual results to differ from those stated or implied in this material.

I. P/L(K-IFRS)

Consolidated base on K-IFRS (Unit : KRW million)	2019					2020					2021	
	1Q	2Q	3Q	4Q	Full Year	1Q	2Q	3Q	4Q	Full Year	1Q	2Q
Sales	6,940	8,264	11,451	10,146	36,801	11,660	8,637	15,185	15,272	50,755	18,284	20,017
Cost of sales	2,684	3,111	4,166	3,521	13,482	3,641	3,115	3,594	5,046	15,394	5,230	6,306
Ratio(%)	39%	38%	36%	35%	37%	31%	36%	24%	33%	30%	29%	32%
Gross profit	4,256	5,153	7,285	6,625	23,318	8,020	5,523	11,592	10,227	35,361	13,054	13,711
Ratio(%)	61%	62%	64%	65%	63%	69%	64%	76%	67%	70%	71%	68%
SG&A	5,320	4,582	5,593	5,077	20,572	5,192	6,323	4,531	7,876	23,922	8,340	7,560
Operating Income	-1,065	571	1,692	1,548	2,746	2,828	-801	7,061	2,351	11,439	4,714	6,151
Ratio(%)	-15%	7%	15%	15%	7%	24%	-9%	46%	15%	23%	26%	31%
Net income before income tax	-1,375	312	1,540	757	1,234	2,850	-2,636	6,735	1,690	8,639	-5,925	5,909
Net Income	-1,353	333	1,553	569	1,102	2,434	-2,622	6,250	1,481	7,543	-6,303	5,634
Ratio(%)	-19%	4%	14%	6%	3%	21%	-30%	41%	10%	15%	-34%	28%
EBITDA	-710	896	2,154	2,013	4,353	3,283	-123	7,603	3,005	13,769	5,289	6,699
Ratio(%)	-10%	11%	19%	20%	12%	28%	-1%	50%	20%	27%	29%	33%

Note1) 2021 1Q _ Other losses (Merger cost KRW 10,569million)

II. Sales by Item (K-IFRS)

Consolidated base on K-IFRS (Unit : KRW million)	2019					2020					2021	
	1Q	2Q	3Q	4Q	Full Year	1Q	2Q	3Q	4Q	Full Year	1Q	2Q
HIFU	1,330	2,014	2,725	2,390	8,460	2,036	2,918	2,207	3,036	10,198	3,304	3,466
RF	642	1,626	1,338	2,127	5,732	2,658	564	1,775	2,638	7,636	4,361	3,293
IPL	1,332	1,037	1,299	1,066	4,734	915	604	889	685	3,093	991	1,029
LASER	1,003	1,081	1,863	1,357	5,304	1,361	781	727	1,342	4,212	1,677	2,074
Consumables	1,768	1,976	2,971	2,914	9,629	4,034	3,008	8,685	6,705	22,432	7,336	9,456
Etc	865	530	1,255	293	2,942	655	762	902	865	3,184	615	699
Total	6,940	8,264	11,451	10,146	36,801	11,660	8,637	15,185	15,272	50,755	18,284	20,017

III. Sales by Channel(K-IFRS)

Consolidated base on K-IFRS (Unit : KRW million)	2019					2020					2021	
	1Q	2Q	3Q	4Q	Full Year	1Q	2Q	3Q	4Q	Full Year	1Q	2Q
Domestic	1,810	1,963	2,085	2,353	8,212	2,208	1,792	2,644	2,377	9,021	2,459	2,848
Overseas	5,129	6,301	9,366	7,793	28,589	9,452	6,845	12,542	12,895	41,734	15,825	17,169
Total	6,940	8,264	11,451	10,146	36,801	11,660	8,637	15,185	15,272	50,755	18,284	20,017

IV. Major Device Sales

Total company (Unit : EA)	2019					2020					2021	
	1Q	2Q	3Q	4Q	Full Year	1Q	2Q	3Q	4Q	Full Year	1Q	2Q
ULTRACel Q+(LinearFirm)	67	116	174	168	525	120	175	126	146	567	164	196
Cumulative Sales	410	526	700	868	-	988	1,163	1,289	1,435	-	1,599	1,795
POTENZA	19	48	43	77	187	100	13	70	91	274	175	99
Cumulative Sales	19	67	110	187	-	287	300	370	461	-	636	735

V. B/S(K-IFRS)

Consolidated base on K-IFRS (Unit : KRW million)	2019					2020					2021	
	1Q	2Q	3Q	4Q	Full Year	1Q	2Q	3Q	4Q	Full Year	1Q	2Q
Current assets	12,904	17,410	17,975	19,725	19,725	21,816	20,097	26,984	28,264	28,264	41,060	39,180
Cash and cash equivalents	633	4,225	3,984	6,083	6,083	7,759	9,533	17,047	17,591	17,591	19,582	23,263
Short-term trade Receivable	7,136	7,756	8,439	4,727	4,727	5,145	3,041	2,562	3,338	3,338	5,945	5,144
Inventories	6,049	6,144	6,259	7,654	7,654	6,993	5,888	5,653	5,766	5,766	6,190	8,171
Non-current assets	6,893	6,832	6,755	8,086	8,086	8,797	10,368	10,153	10,903	10,903	10,829	11,316
Total assets	19,797	24,242	24,730	27,810	27,810	30,613	30,465	37,136	39,167	39,167	51,889	50,496
Current liabilities	25,612	25,800	21,420	23,358	23,358	23,901	10,429	10,668	12,918	12,918	12,957	14,799
Non-current liabilities	5,110	4,978	8,901	13,495	13,495	13,217	16,669	11,157	9,290	9,290	9,936	8,678
Total liabilities	30,722	30,778	30,321	36,853	36,853	37,118	27,098	21,825	22,208	22,208	22,893	23,477
Issued capital	2,048	2,324	2,324	2,048	2,048	2,048	2,767	3,043	3,043	3,043	7,063	7,063
Total equity	-10,925	-6,537	-5,591	-9,043	-9,043	-6,505	3,367	15,312	16,959	16,959	28,996	27,020

Jeisys Medical Inc.

Hang-In Lee (IR Team Manager) / Mail : hilee@jeisys.com